We need to take stock of the promises and limitations of new “miracle” weight loss drugs such as Ozempic, Mounjaro and Wegovy.
Academic rigor, journalistic flair
Articles on Ozempic
Displaying 1 - 20 of 38 articles
The weight-loss drug Wegovy is now in Australia. Here’s what the science says about the potential benefits and risks of taking it.
As far back as the 19th century, teenage girls have been warned about the dangers of weight loss “quack medicines”.
Diabetes drugs similar to Ozempic are associated with a reduction in risk of ten types of cancer compared with treatment with insulin.
The future of the blockbuster drugs could hinge on a trial in Pennsylvania.
Johann Hari’s book opens a deeper conversation about the pros and cons of injectable weight-loss drugs – including whether we really want to trade the pleasure we get from food for losing weight.
Neither Ozempic nor Wegovy are listed on the PBS to treat obesity. When Wegovy becomes available, users will need to pay the full price. Or should the government subsidise it?
The animal studies are promising but early research in humans show mixed results. Here’s what we know so far.
Does weight come back when you stop taking drugs like Ozempic? Are these medications simply another (expensive) form of yo-yo dieting? Here’s what we know so far.
We don’t tell people taking statins to treat high cholesterol or drugs to manage high blood pressure they’re cheating or taking the easy way out. Nor should we when people take drugs like Ozempic.
Many have declared drugs like Ozempic could ‘end obesity’. This isn’t just untrue – it also perpetuates fat stigma.
In Australia, Ozempic is only approved to treat diabetes but doctors are prescribing it ‘off label’ for weight loss. Compounding pharmacies have also been making their own versions to meet demand.
Ozempic generated A$21 billion of sales in 2023 alone. So how was it developed? And how are its new competitors, Mounjaro and Zepbound, different?
Early on we heard a lot about the potential benefits of drugs like Ozempic. Now we’re hearing more about the risks. But what does the latest evidence say?
Laxatives and stool softeners are not designed to be used for weight loss.
The demand for off-label weight loss drugs like Ozempic is concerning, because of the impact on weight stigma and the health risks of unsupervised weight loss, including developing eating disorders.
The first-ever imaging and recording of a brainstem structure critical for feeling full could help reveal exactly how weight loss drugs like Ozempic work, and how to make them more effective.
Weight loss and diabetes drugs target regulatory pathways involved in metabolism that the microbes in your gut and certain molecules from food already play a key role in regulating.
Medications can play an important role in weight management, but not at the expense of overall nutrition. And healthy lifestyle habits are also key.
Drugs for menopause, ADHD and type 2 diabetes were all in short supply this year.
Top contributors
-
Professor and Director - Academic Excellence, Macquarie University
-
General Practitioner, PhD Candidate, Bond University
-
Adjunct Senior Lecturer, Nutrition, Dietetics & Food Innovation - School of Health Sciences, UNSW Sydney
-
Associate Professor of Gastroenterology, School of Medicine, University of Washington
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
-
Accredited Practising Dietitian and Lecturer, Southern Cross University
-
Lecturer, Pharmacy, Aston University
-
Assistant Professor, Critical Disability Studies, Carleton University
-
Associate Lecturer, Sydney Pharmacy School, University of Sydney
-
Practice Pharmacist/Honorary Senior Research Fellow, University of Bradford
-
Laureate Professor in Nutrition and Dietetics, University of Newcastle
-
Associate Professor in Pharmacy Practice, University of Bradford
-
Professor of Community Health and Wellbeing, The University of Queensland
-
The University of Melbourne
-
Senior Lecturer in Physiology, Anglia Ruskin University
